Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03872180 · ClinicalTrials.gov registry record · Phase 2

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma and CCND1 Positive, sponsored by Emory University.

Active
Registry status
Phase 2
Development phase
23
Enrollment target
3
Study locations

NCT03872180 is a Phase 2 study of Mantle Cell Lymphoma and CCND1 Positive that is active but no longer recruiting, run by Emory University. The registered enrollment target is 23 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03872180, a Phase 2 study of Mantle Cell Lymphoma and CCND1 Positive, is active but no longer recruiting, sponsored by Emory University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bendamustine, obinutuzumab, and venetoclax may work better in treating patients with mantle cell lymphoma.

Conditions Studied

Mantle Cell Lymphoma CCND1 Positive t(11;14) Positive

Interventions

  • DRUG Venetoclax
  • BIOLOGICAL Obinutuzumab
  • DRUG Bendamustine

Study Locations (3)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta
  • Emory Johns Creek Hospital - Johns Creek

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2019-04-11
Est. Completion 2026-04-30
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03872180

The ClinicalTrials.gov registry entry for NCT03872180 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (78% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT03872180 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03872180 about?

NCT03872180 is a clinical study titled "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma". This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping th...

What is the current status of trial NCT03872180?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-04-11. Estimated completion is 2026-04-30.

What conditions does trial NCT03872180 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, CCND1 Positive, t(11;14) Positive.

What interventions are being tested in trial NCT03872180?

The interventions under investigation include: Venetoclax (DRUG), Obinutuzumab (BIOLOGICAL), Bendamustine (DRUG).

Who is sponsoring clinical trial NCT03872180?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03872180 being conducted?

This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

CCND1 Positive

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.